Finland submitted its application for the relocation of EMA to Helsinki
Earlier today, Finland submitted its application to host the European Medicines Agency (EMA) that will be relocated from Great Britain.
The Finnish Government and the city of Helsinki have drawn up a precise plan for the transfer of the European Medicines Agency to Helsinki.
Finland is offering a cost-effective, logistically functional and smooth solution to relocate EMA to Helsinki.
The decision on the relocation of the European Medicines Agency will be made on 20 November 2017 by the EU General Affairs Council.
Fimea considers Finland’s candidacy for the new seat of EMA important
The Finnish Medicines Agency Fimea finds it important that Finland is one of the candidates.
– In our opinion, Finland’s application supports the continuity of the operation in the best possible way. We must together ensure that EMA will be able to operate during the transition phase. Pharmaceutical regulation must not suffer under any circumstances, and ensuring a smooth relocation process is a challenge shared by the whole EU, says Director General Sinikka Rajaniemi.
Fimea is part of the European medicines regulatory network consisting of the national medicines agencies, the European Medicines Agency and the European Commission. The task of the European Medicines Agency is to take care of pre and post-marketing control of medicines. EMA also administrates the processes of the centralized marketing authorisation procedure of medicinal products and coordinates the scientific assessment carried out by national agencies.
- Sinikka Rajaniemi, Director General, tel. + 358 29 522 3110
- Eija Pelkonen, Director, tel. + 358 29 522 3210
- The e-mail addresses have the form firstname.lastname@example.org.